2024
Positive flow crossmatches due to anti-ABO red blood cell antibodies
Rewinski M, Doyle P, Devivo J, Vicki S, Durkin D, Caruk R, Bow L. Positive flow crossmatches due to anti-ABO red blood cell antibodies. Human Immunology 2024, 85: 111019. DOI: 10.1016/j.humimm.2024.111019.Peer-Reviewed Original Research
2023
P111 Navigating through discordant results towards a successful transplant
Rewinski M, Doyle P, Bow L. P111 Navigating through discordant results towards a successful transplant. Human Immunology 2023, 84: 69. DOI: 10.1016/j.humimm.2023.08.013.Peer-Reviewed Original Research
2022
210.15: MRNA Based Vaccines Against SARS-CoV-2 Do Not Alter cPRA in Patients Awaiting Kidney Transplant
Rewinski M, Doyle P, Durkin D, Vicki S, Devivo J, Caruk R, Haberman A, Palmeri D, Cyr P, Morgan G, Serrano O, Emmanuel B, Ebcioglu Z, Singh J, Kent R, Ye X, Tremaglio J, Bow L, Dar W. 210.15: MRNA Based Vaccines Against SARS-CoV-2 Do Not Alter cPRA in Patients Awaiting Kidney Transplant. Transplantation 2022, 106: s9-s10. DOI: 10.1097/01.tp.0000885248.19450.6c.Peer-Reviewed Original Research
2019
P018 Interpreting positive crossmatches with allele specific antibodies
Rewinski M, Doyle P, DeVivo J, Vicki S, Durkin D, Bow L. P018 Interpreting positive crossmatches with allele specific antibodies. Human Immunology 2019, 80: 68. DOI: 10.1016/j.humimm.2019.07.070.Peer-Reviewed Original ResearchP020 Comprehensive HLA typing and antibody testing reaffirms an acceptable donor–recipient exchange
Rewinski M, Doyle P, DeVivo J, Vicki S, Durkin D, Bow L. P020 Comprehensive HLA typing and antibody testing reaffirms an acceptable donor–recipient exchange. Human Immunology 2019, 80: 70. DOI: 10.1016/j.humimm.2019.07.072.Peer-Reviewed Original ResearchP022 Case study: A closer look for DSA in a zero antigen mismatch kidney transplant recipient
Miller M, Bow L. P022 Case study: A closer look for DSA in a zero antigen mismatch kidney transplant recipient. Human Immunology 2019, 80: 72. DOI: 10.1016/j.humimm.2019.07.074.Peer-Reviewed Original ResearchP170 Can FBS expeditiously reduce non-specific reactivity in pre-transplant heart recipients?
Miller M, Warner M, Bow L. P170 Can FBS expeditiously reduce non-specific reactivity in pre-transplant heart recipients? Human Immunology 2019, 80: 192. DOI: 10.1016/j.humimm.2019.07.223.Peer-Reviewed Original ResearchP194 What’s in your unacceptable antigen toolbox? lifecodes validation at yale
Miller M, Rivera J, Bow L. P194 What’s in your unacceptable antigen toolbox? lifecodes validation at yale. Human Immunology 2019, 80: 209. DOI: 10.1016/j.humimm.2019.07.247.Peer-Reviewed Original Research
2018
P026Timing is everything – Even for DP antibodies
Rewinski M, Doyle P, Bow L. P026Timing is everything – Even for DP antibodies. Human Immunology 2018, 79: 80. DOI: 10.1016/j.humimm.2018.07.084.Peer-Reviewed Original ResearchDonor-specific antibodiesTransplant glomerulopathyKidney transplantSensitizing eventsAbsence of DSADevelopment of DSALevels of DSADeceased donor kidney transplantDP typingPotential sensitizing eventsReduced graft survivalDonor kidney transplantsArteriolar hyalinosisBK viremiaKidney TxNegative XMPositive XMStandard immunosuppressionCNI toxicityGraft survivalBlood transfusionGraft failureAntibody testingAntibody responseDP antigensP032 Edta elucidates unexpected crossmatch results
Rewinski M, Doyle P, DeVivo J, Vicki S, Durkin D, Bow L. P032 Edta elucidates unexpected crossmatch results. Human Immunology 2018, 79: 84. DOI: 10.1016/j.humimm.2018.07.090.Peer-Reviewed Original ResearchPatient seraAntibody profileDeceased donor kidney transplantClass IDonor kidney transplantsKidney TxDSA levelsKidney transplantFlow crossmatchUnacceptable antigensCrossmatch resultsT cellsMFI levelsAb reactivityAntibody detectionAsian malesPossible epitopesCourse of monthsSerumAb profilesAO treatmentSignificant differencesSignificant increaseTreatmentDD cellsP038 Donor specific anti-a titer for abo incompatible (ABOi) living kidney transplantation
Miller M, Bow L. P038 Donor specific anti-a titer for abo incompatible (ABOi) living kidney transplantation. Human Immunology 2018, 79: 88. DOI: 10.1016/j.humimm.2018.07.096.Peer-Reviewed Original ResearchABO-incompatible donorsKidney transplantationLiving donorsRed cellsTiter resultsA2 red cellsBlood group A antigensReactive IgG antibodiesTime of transplantGroup A antigensKidney donor programsBlood group BABOi transplantsRejection episodesRecipient serumAbsolute contraindicationDonor transplantsIgG titersDeceased donorsDonor optionsIgG antibodiesGroup BA antigenIncompatible donorsA2 cellsP039 The bumpy road to epic beaker implementation
Miller M, Bow L. P039 The bumpy road to epic beaker implementation. Human Immunology 2018, 79: 88. DOI: 10.1016/j.humimm.2018.07.097.Peer-Reviewed Original Research
2017
OR51 Correlation of class II antibody development with acute cellular rejection and fibrosis in pediatric liver transplantation
Bow L, Ekong U, Morotti R, Antala S, Emre S. OR51 Correlation of class II antibody development with acute cellular rejection and fibrosis in pediatric liver transplantation. Human Immunology 2017, 78: 47. DOI: 10.1016/j.humimm.2017.06.057.Peer-Reviewed Original ResearchAcute cellular rejectionClass II DSAPediatric liver transplantationLiver transplantationCellular rejectionHLA antibodiesFibrosis scoreDe novo HLA antibodiesNovo HLA antibodiesSided p valueDiagnosis of antibodyWilcoxon rank sumContinuous variablesGraft dysfunctionMean fibrosisSinusoidal fibrosisGraft functionPost transplantRejection gradeAvailable biopsiesLiver dysfunctionPatient characteristicsAntibody levelsDSA developmentSpecificity of antibodies
2016
P148 Uncovering antibodies to cryptic epitopes: Use of flow cytometry crossmatch to differentiate between functional and denatured epitopes
Mangiola M, Lomago J, Marilyn M, Nichol L, Zern D, McGowan K, Sese D, Bow L, Zeevi A. P148 Uncovering antibodies to cryptic epitopes: Use of flow cytometry crossmatch to differentiate between functional and denatured epitopes. Human Immunology 2016, 77: 145. DOI: 10.1016/j.humimm.2016.07.213.Peer-Reviewed Original ResearchAntigen beadsCryptic epitopesFlow cytometry crossmatchSingle antigen beadsSmall bowel transplantHLA antibody detectionClass II profileBowel transplantCytometry crossmatchDR antigensHLA AbsDR7 allelesPatient beingCrossmatch requestsAntibody detectionSurrogate donorsMolecular typingFlow cytometryExon 2Ab profilesPotential targetPatient cellsEpitopesPatientsPremature stop codonP054 EDTA treatment of serum eliminates interference in flow cytometric crossmatches
Rewinski M, Ortiz J, Alberghini T, Bow L, Devivo J, Doyle P, Michalski T. P054 EDTA treatment of serum eliminates interference in flow cytometric crossmatches. Human Immunology 2016, 77: 78. DOI: 10.1016/j.humimm.2016.07.119.Peer-Reviewed Original ResearchT cell populationsPatient seraMedian fluorescence intensityT cellsComplement proteinsControl seraUntreated patients' seraFlow cytometric crossmatchDonor cellsSignificant T-cellCell populationsOccasional false positive resultsHigh-titer antibodiesPatient serum samplesCytometric crossmatchFlow crossmatchAntibody testingFalse-positive resultsIgM antibodiesPositive control seraMFI levelsNegative control seraTiter antibodiesSerum samplesSerumP002 The consistent inconsistency in HLA antibody testing practices: a collaboration with the Banff workgroup
Dadhania D, Jackson A, Campbell P, Bow L, Almeshari K, Schinstock C, Cornell L, Bagnasco S, Kraus E, Cozzi E, Askar M. P002 The consistent inconsistency in HLA antibody testing practices: a collaboration with the Banff workgroup. Human Immunology 2016, 77: 41. DOI: 10.1016/j.humimm.2016.07.067.Peer-Reviewed Original ResearchDonor-specific HLA antibodiesSingle antigen beadsHLA AbsAntigen beadsNon-sensitized patientsSpecific HLA antibodiesLarge transplant centerDifferent practice patternsDiagnosis of antibodyBanff criteriaHLA antibodiesSensitization statusSurveillance biopsiesPatients 54Transplant centersCombination of assaysPatient outcomesStrong antibodyPractice patternsPatient variesTesting practicesClinical relevanceHistocompatibility laboratoriesProzone effectAntibodies
2015
Establishing a Next Generation Sequencing laboratory for high resolution HLA typing
McGowan K, Bow L. Establishing a Next Generation Sequencing laboratory for high resolution HLA typing. Human Immunology 2015, 76: 101. DOI: 10.1016/j.humimm.2015.07.146.Peer-Reviewed Original ResearchCase study: Use of A2 and donor red blood cells for anti ABO a titer
Miller M, Bow L. Case study: Use of A2 and donor red blood cells for anti ABO a titer. Human Immunology 2015, 76: 97. DOI: 10.1016/j.humimm.2015.07.141.Peer-Reviewed Original ResearchDonor RBCsIgG titersABO incompatibilityTransplant programsBlood group O recipientsBlood group A antigensWeak antigen expressionABO-incompatible transplantsGroup O recipientsBlood group OYear old maleGroup A antigensBlood group AA1 RBCsABOi transplantsIncompatible transplantsKidney transplantationRecipient serumAbsolute contraindicationKidney transplantRed blood cellsAntibody titersAntigen subtypesO recipientsIgG antibodiesNovel antigen expression of HLA-DR53 in patients with DR7 and DQ9 haplotype
Rivera J, Rewinski M, Bow L, DeVivo J, Michalski T, Alberghini T, Doyle P. Novel antigen expression of HLA-DR53 in patients with DR7 and DQ9 haplotype. Human Immunology 2015, 76: 122. DOI: 10.1016/j.humimm.2015.07.171.Peer-Reviewed Original ResearchPositive B cell crossmatchB-cell crossmatchDR/DQAllocation of organsPossibility of antibodySerology typingHLA-DR53HLA phenotypesReflex testingCaucasian patientsLeukemia patientsReal-time PCRAntigen expressionOrgan donorsPatientsDR53 antigenDR53AntibodiesAdditional typingGenotype associationsAntigenTypingCommon null alleleRecipientsUnexpected expressionConundrum: A negative crossmatch in a patient with high level donor specific antibody
Rewinski M, Alberghini T, Bow L, Devivo J, Doyle P, Michalski P, Ortiz-Rivera J. Conundrum: A negative crossmatch in a patient with high level donor specific antibody. Human Immunology 2015, 76: 57. DOI: 10.1016/j.humimm.2015.07.082.Peer-Reviewed Original ResearchDonor-specific antibodiesB-cell crossmatchDonor-recipient pairsNegative crossmatchMedian fluorescence intensityVirtual crossmatchPresence of DSAPositive B cell crossmatchSpecific antibodiesIncompatible donor-recipient pairsFlow crossmatchAntibody levelsPositive donorsSAB assayAntibody testingHigh-resolution typingClinical significanceT cellsHLA typingPatient seraCrossmatchEP serumClass IIDQ7RT-PCR